Gelesis Holdings Long Term Debt 2021-2022 | GLS

Gelesis Holdings long term debt from 2021 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Gelesis Holdings Annual Long Term Debt
(Millions of US $)
2021 $
2020 $
2019 $
Gelesis Holdings Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $34
2021-12-31 $35
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.104B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00